CAR-T Treatment in Glioblastoma: Will the Effect Be Sustaine
A significantly powerful form of immunotherapy, the chimeric antigen receptor (CAR)-T–cell treatment has so far been developed in patients with hematological cancers. However, a new single-patient case study, published in the New England Journal of Medicine, has raised the possibility of using CAR-T cells in the treatment of glioblastoma, an aggressive form of brain tumor.

The treatment was provided at City of Hope to a 50-year-old man who presented with glioblastoma in the right temporal lobe. Following standard treatment of tumor resection, radiation, and temozolomide, the patient relapsed. At that point, the patient was enrolled in a study evaluating the safety and efficacy of IL13R?2-targeted CAR-T cells. IL13R?2 is a glioma-associated antigen linked to a reduced rate of survival. The authors wrote that based on their previous study, they improved the antitumor potency and T cell persistence of the IL13R?2-targeted CAR-T cells by including a 4-1BB (CD137) costimulation domain and a mutated IgG4-Fc linker.

- See more at: http://www.ajmc.com/newsroom/car-t-treatment-in-glioblastoma-will-the-effect-be-sustained#sthash.R1TjtMn0.dpuf
Like
Comment
Share